Cumberland Pharmaceuticals Inc. — Q2 2023 Form 10-Q Summary
Business Context and Reporting Period
Cumberland is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology. The filing covers the three and six months ended June 30, 2023. The financial statements are unaudited. The company reported 14,371,214 common shares outstanding as of August 7, 2023.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Net revenues | $10.9 million, versus $10.3 million | $20.1 million, versus $21.5 million |
| Operating income (loss) | $0.02 million, versus $(1.85) million | $(1.51) million, versus $(3.14) million |
| Net income (loss) attributable to common shareholders | $0.87 million, versus $(1.34) million | $1.06 million, versus $(2.72) million |
| Diluted EPS | $0.06, versus $(0.09) | $0.07, versus $(0.19) |
| Net cash provided by operating activities | $3.82 million, versus $2.18 million |
- Second-quarter gross margin was approximately 86.0%, compared with 80.3% in the prior-year quarter. First-half gross margin was approximately 86.2%, compared with 80.2%.
- Second-quarter operating margin was approximately 0.2%, compared with negative 17.9% in the prior-year period. First-half operating margin was negative 7.5%, compared with negative 14.6%.
- June 30 cash and cash equivalents were $18.25 million, compared with $19.76 million at December 31, 2022. Working capital was $16.72 million and the current ratio was 1.6.
- Revolving credit borrowings were $13.15 million, down from $16.20 million at year-end, with reported availability of $6.85 million. The facility has a $20 million principal limit, matures October 1, 2024, is secured by substantially all company assets, and carried an 8.0% interest rate at June 30, 2023.
- The company was in compliance with its Funded Debt Ratio covenant at quarter-end. The benchmark transitioned from LIBOR to Term SOFR beginning June 30, 2023.
- Total assets were $89.38 million and total equity was $36.84 million at June 30, 2023. The company reported approximately $53.1 million of federal net operating loss carryforwards and expects minimal cash taxes during 2023 and beyond.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue increased $0.59 million, driven primarily by higher Kristalose and Vibativ sales and $1.30 million of other revenue. First-half revenue declined $1.36 million, primarily because Sancuso revenue fell $2.99 million.
- Sancuso second-quarter revenue declined to $1.92 million from $3.40 million, reflecting larger product returns and increased sales deductions. The company expanded its oncology sales division in June and launched supplies from a newly approved manufacturing facility.
- Kristalose revenue increased 12.1% in the second quarter and 12.1% for the first half, while Vibativ revenue increased 34.5% in the second quarter but declined 2.5% for the first half.
- Cost of products sold decreased 25.1% in the second quarter and 34.7% for the first half, reflecting lower-cost inventory and fewer inventory write-downs.
- Research and development expense declined 37.2% in the second quarter and 25.9% for the first half, primarily due to lower FDA fees. General and administrative expense increased 7.5% in the second quarter and 8.0% for the first half, including higher deferred compensation and hiring costs.
- Operating cash flow improved to $3.82 million from $2.18 million. Cash was used for $3.05 million of net revolving-credit repayments, $1.65 million of contingent consideration payments and $0.35 million of share repurchases.
Guidance, Outlook, Risks and Unusual Items
- No formal numerical revenue or earnings guidance is provided. Management stated that existing working capital, internally generated cash flow and the revolving credit facility are expected to fund internal growth, business development initiatives and capital expenditures for the foreseeable future.
- Management is continuing Phase II ifetroban programs in Duchenne muscular dystrophy and systemic sclerosis and plans to launch a Phase II idiopathic pulmonary fibrosis study. The company received FDA clearance to proceed with the latter program.
- The company recognized $2.83 million of other income in the first half from FDA prescription drug fee waivers, including $1.0 million in the second quarter. It also recognized approximately $1.0 million related to a settlement of Vibativ milestone-payment litigation.
- Vaprisol remains unavailable commercially while a new manufacturing facility addresses FDA Form 483 and warning-letter issues. Omeclamox-Pak also remains unavailable because its packager experienced financial difficulties; the company is evaluating resumption alternatives.
- RediTrex commercialization transferred to Nordic effective July 1, 2023. Cumberland received returned shares, a $1.0 million milestone refund and a $1.0 million credit note, and will receive royalties on future Nordic sales through April 2035.
- Key risks include product supply interruptions, regulatory and manufacturing approvals, product returns and sales deductions, dependence on successful product commercialization and acquisitions, clinical-development uncertainty, inflation, rising interest rates, limited borrowing capacity and the October 2024 debt maturity.
- The company reported no material adverse effect expected from existing litigation and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective.
Important Facts for Investors to Verify
- Whether Sancuso sales stabilize following elevated returns and the expanded oncology sales effort.
- The timing and regulatory status of Vaprisol manufacturing approval and Omeclamox-Pak supply recovery.
- Availability under, interest costs on and covenant compliance for the revolving credit facility before its October 2024 maturity.
- Whether FDA fee refunds and the Vibativ settlement are nonrecurring and how results perform excluding these items.
- Enrollment, safety, efficacy and funding requirements for the ifetroban Phase II programs, including the planned idiopathic pulmonary fibrosis trial.
- The sustainability of operating cash flow as inventory, contingent consideration and product-related working-capital requirements change.